Immuneering

Recent Finacing

Series B

Recent Raise

$62M

Immuneering applies bioinformatics and its proprietary Disease Cancelling Technology to discover small-molecule therapeutics across oncology, neuroscience, and immuno-oncology and provides computational biology services to pharma and biotech.

Founded 2008

Massachusetts, United States

51-100

Publicly Traded

immuneering.com

Highlights

Focus Areas

Biotechnology

Medical

Pharmaceutical

Recent Investors

B

Financials

$82M

Total Raised

2

Funding rounds

8

Investors

Team

Upgrade to view the team

See the team members at Immuneering.